Inventors:
David Weinshenker - Atlanta GA, US
Robert T. Malison - Guilford CT, US
International Classification:
A61K 31/415, A61P 25/30, C12Q 1/68
Abstract:
The present disclosure relates to methods of treating a stimulant addiction of a patient comprising administering to a patient in need a therapeutically effective dose of a selective dopamine β-hydroxylase inhibitor thereby decreasing stimulant reward, inducing aversion for the stimulant or preventing relapse in the patient. The disclosure further encompasses methods whereby a therapeutically effective dose of a selective dopamine β-hydroxylase inhibitor is determined by: characterizing the genetic profile of the patient with respect to the gene encoding dopamine β-hydroxylase, a polymorphism therein correlating to the level of endogenous dopamine β-hydroxylase activity in the patient before administering the therapeutic agent.